International Journal of Hematology

DOI: 10.1007/s12185-017-2316-z Pages: 612-621

Effect of rituximab on primary central nervous system lymphoma: a meta-analysis

1. The First Affiliated Hospital of Zhengzhou University, Department of Medical Oncology

2. The First Affiliated Hospital of Zhengzhou University, Institute of Clinical Medicine

3. Lymphoma Diagnosis and Treatment Centre of Henan Province

4. The First Affiliated Hospital of Zhengzhou University, Department of Urodynamics Centre

Correspondence to:
Mingzhi Zhang
Email: mingzhi_zhang1@163.com

Close

Abstract

The effect of rituximab on primary central nervous system lymphoma (PCNSL) is controversial. We performed this meta-analysis to assess the efficacy of treatment with or without rituximab for PCNSL. We first conducted a search for qualified studies using PubMed, the Cochrane Library, and the Web of Science. The meta-analysis was conducted to compare odds ratios (ORs) with the corresponding 95% confidence interval (95% CI) for complete remission (CR) rate, progression-free survival (PFS), and overall survival (OS) using Review Manager 5.0. We included two randomized clinical trials and six retrospective studies in this meta-analysis. The results of our statistical analysis show that the use of rituximab was closely correlated with a higher CR (OR 1.70, 95% CI 1.17–2.46, P = 0.005), 2-year PFS (OR 2.11, 95% CI 1.08–4.11, P = 0.03), 5-year PFS (OR 2.54, 95% CI 1.64–3.93, P < 0.0001), 2-year OS (OR 2.40, 95% CI 1.73–3.34, P < 0.00001), and 5-year OS (OR 2.87, 95% CI 2.02–4.08, P < 0.00001). These results may help to inform therapeutic strategies including the use of rituximab and to improve therapeutic planning for PCNSL patients.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge